Skip to content
Disclosery

venBio Partners LLC

Follow

13F filer, CIK 1776382, SAN FRANCISCO, CA

venBio Partners LLC reported $216,272,926 across 6 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000905148-26-000841

Period
2025-12-31
Reported value
$216M
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELreduced-135,782-$4.18M
ARTVreduced-500,468-$2.15M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0000905148-26-000841, largest first. % of portfolio is the value over $216,272,926, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,289,304 shares; 2024Q4: 4,289,304 shares; 2025Q1: 4,289,304 shares; 2025Q2: 4,289,304 shares; 2025Q3: 4,639,304 shares; 2025Q4: 4,639,304 shares 4,639,304$129M59.53%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,826,048 shares; 2024Q4: 2,787,398 shares; 2025Q1: 2,787,398 shares; 2025Q2: 4,619,803 shares; 2025Q3: 4,619,803 shares; 2025Q4: 4,619,803 shares 4,619,803$45.1M20.85%0Timeline
HRMYHARMONY BIOSCIENCES HLDGS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 614,594 shares; 2024Q4: 539,194 shares; 2025Q1: 489,194 shares; 2025Q2: 489,194 shares; 2025Q3: 489,194 shares; 2025Q4: 489,194 shares 489,194$18.3M8.46%0Timeline
ALXOALX ONCOLOGY HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,699,925 shares; 2024Q4: 9,699,925 shares; 2025Q1: 9,699,925 shares; 2025Q2: 9,699,925 shares; 2025Q3: 9,699,925 shares; 2025Q4: 9,699,925 shares 9,699,925$11M5.07%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 473,479 shares; 2025Q3: 473,479 shares; 2025Q4: 337,697 shares 337,697$10.4M4.81%-135,782Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,519,971 shares; 2024Q4: 1,519,971 shares; 2025Q1: 1,198,975 shares; 2025Q2: 1,148,975 shares; 2025Q3: 1,148,975 shares; 2025Q4: 648,507 shares 648,507$2.78M1.29%-500,468Timeline

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000905148-26-000841 base2026-02-17acceptance time not in the bulk data set